Show simple item record

dc.contributor.authorGuirado, Macarena
dc.contributor.authorGil, Hernani
dc.contributor.authorSáenz-López, Pablo
dc.contributor.authorReinboth, Jennifer
dc.contributor.authorGarrido Torres-Puchol, Federico 
dc.contributor.authorCózar Olmo, José Manuel 
dc.contributor.authorRuiz-Cabello Osuna, Francisco 
dc.contributor.authorCarretero Coca, Rafael
dc.date.accessioned2025-11-04T08:33:49Z
dc.date.available2025-11-04T08:33:49Z
dc.date.issued2012-06
dc.identifier.citationHum Immunol. 2012 Jun;73(6):668-72. doi: 10.1016/j.humimm.2012.03.006. Epub 2012 Apr 12.es_ES
dc.identifier.urihttps://hdl.handle.net/10481/107726
dc.description.abstractSeveral evidences have been published linking polymorphism in genes involved in chronic or recurrent inflammation with increased tumor risk and progression. Nevertheless the influence of innate immune receptors in urothelial cancer risk and characteristics has not been sufficient explored. We studied the possible association of polymorphisms in genes encoding NOD2, RIPK2, TLR10 and C13ORF31 with the risk, clinical/pathological characteristics and outcomes of urothelial cancer. We have found association between RIPK2 (rs42490) and cancer risk (AA vs AT&TT, p=0042). In addition, we found statistical differences in TLR10 (rs4129009) gen between low and high tumor infiltration stage (p=0.033). NOD2 (rs9302752) and RIPK2 (rs42490) were found to be associated with development of lymph node metastasis (p=0.011 and p=0.015). Importantly we detect association of TLR10 (Log Rank=0.035) and RIPK2 (Log Rank=0040) with overall survival. Multivariate Cox analysis revealed that both SNPs were survival prognosis factor independent of tumor stage and grade. Our results indicate that innate immunity receptors play a role in modulating urothelial cancer risk and progression.es_ES
dc.description.sponsorshipDepartamento de Bioquímica III e Inmunología, Universidad de Granada, Spaines_ES
dc.description.sponsorshipServicio de Urología, Hospital Universitario Virgen de las Nieves, Granada, Spaines_ES
dc.description.sponsorshipServicio de Análisis Clínicos e Inmunología, Hospital Universitario Virgen de las Nieves, Granada, Spaines_ES
dc.description.sponsorshipGenelux Corporation, San Diego Science Center, San Diego, CA, USAes_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectC13ORF31es_ES
dc.subjectNOD2es_ES
dc.subjectRIPK2es_ES
dc.subjectTLR10es_ES
dc.subjectCanceres_ES
dc.subjectPrognosis es_ES
dc.subjectPolymorphismes_ES
dc.subjectbladderes_ES
dc.titleAssociation between C13ORF31, NOD2, RIPK2 and TLR10 polymorphisms and urothelial bladder canceres_ES
dc.typejournal articlees_ES
dc.rights.accessRightsembargoed accesses_ES
dc.identifier.doi10.1016/j.humimm.2012.03.006
dc.type.hasVersionAMes_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional